Suvemcitug Plus Chemotherapy Improved Survival Outcomes Among Patients With Platinum-Resistant Ovarian Cancer

According to results from the phase 3 SCORES study, suvemcitug, a new-generation recombinant humanized anti-VEGF rabbit monoclonal antibody, in combination with chemotherapy demonstrated improvements in progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR) among patients with platinum-resistant ovarian cancer.

These results were first presented by Guangwen Yi, MD, National Cancer Center/National Clinical Research Center, Beijing, China, at the 2024 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois.

In this double-blinded, placebo-controlled, phase 3 trial, 421 patients with platinum-resistant ovarian cancer, who had progressed were enrolled. Investigators chose chemotherapy for each patient (paclitaxel, peylated liposomal doxorubicin, or topotecan) and patients were then randomized on a 2-to-1 basis to receive either 1.5 mg/kg suvemcitug once every 2 weeks plus chosen chemotherapy (n = 281), or placebo plus chosen chemotherapy (n = 140). The primary end point of this study was PFS as assessed by a blinded independent review committee (BIRC) and the key secondary end point was overall survival (OS).

With a median follow-up duration of 14.36 months in the suvemcitug arm and 14.26 in the placebo arm, the median PFS was 5.49 months and 2.73 months respectively (hazard ratio [HR], 0.46; P < .0001). While OS data are immature, there is a trend of OS benefit with suvemcitug (median OS: 16.07 vs 14.88; HR, 0.79; P = .1244). The ORR by BIRC was 26.0% in the suvemcitug arm vs 12.1% in the placebo arm. The DCR by BIRC was 76.5% vs 49.3%, respectively. All patients in the suvemcitug arm experienced a treatment-emergent adverse event with the most common being neutrophil count decreased, white blood cell decreased, and platelet count decreased. There were no suvemcitug-related grade 5 treatment-emergent adverse events.

Dr Yuan concluded, “Suvemcitug plus chemotherapy showed efficacy improvement compared to chemotherapy whether or not [patients] previously received antiangiogenic agents or PARP inhibitors” and “showed a statistically significant and clinically meaningful PFS improvement across all pre-defined subgroups.”

Source:

Yuan G, Wu L, Li Q, et al. A phase III randomized, double-blinded, placebo-controlled study of suvemcitug combined with chemotherapy for platinum-resistant ovarian cancer (SCORES). Presented at 2024 ASCO Annual Meeting. May 31-June 4, 2024; Chicago, Illinois. Abstract #LBA5515